Detailed Narrative
Q1 FY27 Performance Overview
Alkem Laboratories reported a revenue from operations of INR3,740 crores for Q1 FY27, marking an 11% year-on-year growth. This was supported by strong international sales, which grew 16% to INR1,222 crores, and a 10.3% increase in India sales to INR2,497 crores. The company's EBITDA margin stood at 20.5%, with profit before tax showing a flattish growth of 1.8%, while net profit experienced a 21.7% degrowth primarily due to taxation reasons.
Indian Market Outperformance and Segment Dynamics
The company significantly outperformed the Indian pharmaceutical market (IPM), growing 13.2% against IPM's 12.2%, an outperformance of 100 basis points. This was driven by strong performance in both Acute (12.3% vs IPM 10.1%) and Chronic (17.9% vs IPM 15.4%) segments. However, overall India growth was impacted by the Trade Generics business, which saw flattish to mild growth due to intense competition and tightened internal policies, contrasting with the 12% growth in branded generics.
International Business and US Regulatory Landscape
International sales demonstrated robust growth of 16% year-on-year. In the US market, Alkem received 5 ANDA approvals, including one tentative approval. A key development was the OAI status received by the Daman facility, which contributes 45% of the company's US revenue. Management has initiated corrective actions and expects resolution within 6-12 months, assuring that product supplies to the US market remain uninterrupted.
New Ventures: CDMO and Acquisitions
The US CDMO operation incurred a significant operational expense of INR60 crores for the quarter and is projected to breakeven in 4-5 quarters, requiring USD25-30 million in annualized revenue, with revenue kick-in expected by FY28. The Occlutech acquisition, closed mid-July, targets INR400 crores in sales with breakeven EBITDA for the remaining 8.5 months of FY27, with long-term margin improvement of 7-8% year-on-year over 3-4 years.
Cost Structure and Profitability Outlook
Employee costs increased by over 16% due to annual increments, the addition of 1,200 MRs, and the operationalization of the Enzene CDMO business. Other expenses also rose due to the CDMO venture and higher dollar conversion rates for foreign subsidiaries. The consolidated tax rate for the full year is expected to be 30-32%, higher than the standalone rate, due to losses in entities like Enzene US where deferred tax assets are not yet recognized.
Biosimilar Pipeline and Strategic Focus
The launch of the Denosumab biosimilar in the US has been pushed off by a few months from its goal date. In Europe, the Xgeva biosimilar launch is anticipated in approximately three months. The company's India biosimilar portfolio, with 7 products launched, is generating around INR150 crores in annual sales, benefiting from backward integration and improved margins. Management reiterated its focus on disciplined growth, particularly in the Trade Generics segment.